SEC ownership of EUPRAXIA PHARMACEUTICALS INC.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001581178.

Comparable stake leader

Joseph S. Freedman

Disclosed value leader

Joseph S. Freedman

Comparable rows

50/50

Latest evidence

31 Mar 2026

Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 3 signals
Comparable ownership rows
50 of 50
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder
Joseph S. Freedman
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date
31 Mar 2026
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001581178
Issuer location
Vancouver

Ownership snapshot

Top shareholders of EUPRAXIA PHARMACEUTICALS INC. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Joseph S. Freedman
Disclosed value leader
Joseph S. Freedman
Comparable rows
50/50
Latest evidence
31 Mar 2026
13D/G 13F Lead comparable stake: 9% 13D/G row: Joseph S. Freedman Showing 1-8 of 50 holder rows.

Quick read

Joseph S. Freedman leads the comparable SEC ownership view at 9%.

50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Joseph S. Freedman's linked filing trail.
Comparable ownership Top 5
Joseph S. Freedman 9%
Beutel, Goodman & Co Ltd. 8%
MANCHESTER MANAGEMENT CO LLC 7.7%
Robert Disbrow 7%
Affinity Asset Advisors, LLC 3%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 50 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Joseph S. Freedman
13D/G
9%
$47,037,881
5,843,215 shares
+$2,495,500 13 Mar 2026
Beutel, Goodman & Co Ltd.
13F 13D/G
Company
8%
from 13D/G
$26,377,000
3,666,465 shares
31 Mar 2026
MANCHESTER MANAGEMENT CO LLC
13D/G
Morgan C. Frank
7.7%
$28,829,481
4,015,248 shares
-$6,384,994 31 Mar 2026
Robert Disbrow
13D/G
7%
$21,052,085
3,568,150 shares
$0 30 Sep 2025
Affinity Asset Advisors, LLC
13F
Company
13F
3%
$11,504,396
1,589,005 shares
31 Mar 2026
BALYASNY ASSET MANAGEMENT L.P.
13F
Company
13F
2.6%
$9,774,000
1,350,000 shares
31 Mar 2026
Vivo Capital, LLC
13F
Company
13F
2.6%
$9,774,000
1,350,000 shares
31 Mar 2026
SCOTIA CAPITAL INC.
13F
Company
13F
2.6%
$7,244,058
1,342,178 shares
31 Mar 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 22 Jul 2025.

Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 0 Shares: 0
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 0 $0 $0 $0
3-6 0 0 $0 $0 $0
6-9 0 0 $0 $0 $0
9-12 0 0 $0 $0 $0

Recent insider transactions for EUPRAXIA PHARMACEUTICALS INC.

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
No insider transactions were found in the last 12 months for this issuer.
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .